- Frozen (CL092) $ 1,800
Cell type: Colorectal Cancer
Transgenes: Firefly luciferase (Fluc) with neomycin resistance (Neo) for selection with G418 and near-infrared fluorescent protein (iRFP) with puromycin resistance (Puro) for selection with puromycin
Media: DMEM, 10% FBS, 1% Pen/Strep, 0.4 mg/mL G418, 3 μg/mL puromycin
CT26.WT-Fluc-Neo/iRFP-Puro is a polyclonal population of the colorectal carcinoma cell line CT26.WT (ATCC® CRL-2638™) transduced with 1) LV-Fluc-P2A-Neo (LV011) encoding the firefly luciferase (Fluc) cDNA under the spleen focus-forming virus (SFFV) promoter linked to the neomycin resistance gene (Neo) via a P2A cleavage peptide and 2) LV-iRFP-P2A-Puro (LV032) encoding the near-infrared fluorescent protein (iRFP) cDNA under the spleen focus-forming virus (SFFV) promoter linked to the puromycin resistance gene (Puro) via a P2A cleavage peptide.
The lentiviral vector used is a self-inactivating (SIN) vector in which the viral enhancer and promoter has been deleted. Transcription inactivation of the LTR in the SIN provirus increases biosafety by preventing mobilization by replication competent viruses and enables regulated expression of the genes from the internal promoters without cis-acting effects of the LTR (Miyoshi et al., J Virol. 1998).
The CT26.WT-Fluc-Neo/iRFP-Puro cell line has been tested for mycoplasma contamination and is certified mycoplasma free.
Cell Line Authentication:
The parental CT26.WT cell line was authenticated and certified free of interspecies cross-contamination by short tandem repeat (STR) profiling with 27 STR loci.
In vitro: This is a high luciferase and iRFP expressing cell line suitable for use as a positive control cell line in bioluminescence and fluorescence assays to verify luciferase or iRFP expression respectively in your lentiviral transduced cells.
In vivo: CT26.WT cells form tumors post implantation into mice. The in vivo growth of these tumors can be monitored using noninvasive bioluminescent imaging or noninvasive optical imaging for iRFP.
Note: Please ensure that your optical imaging system has the appropriate filters for iRFP detection (ex/em = 690/713 nm).
Morphology: Low- and high-density cell morphology (200x)
Luciferase Assay: 104, 105, or 106 cells were placed in wells of a 96-well plate and 0.3 mg of d-luciferin was added to the indicated wells. The plate was immediately imaged using a Xenogen IVIS Spectrum.
Flow cytometry for iRFP: CT26.WT-Fluc-Neo/iRFP-Puro cells (red) or control (CT26.WT-Fluc-Neo; grey) cells were fixed with paraformaldehyde and analyzed by flow cytometry (20,000 events).
Bioluminescent images showing growth of a subcutaneous CT26.WT-Fluc tumor in an athymic mouse
107 CT26.WT-Fluc-Neo cells (Imanis Life catalog #CL043) were injected subcutaneously into the right flanks of female NCR athymic mice. Mice were imaged at day 0 on the day of cell implantation and subsequently at days 7 and 11 using a Perkin Elmer IVIS® Spectrum system, at 10-15 minutes post intraperitoneal injection of D-luciferin at 150 mg/kg. Tumor size was measured using calipers. Data from a representative mouse (ID#5815) is shown.